Affimed N.V. (AFMD)
Automate Your Wheel Strategy on AFMD
With Tiblio's Option Bot, you can configure your own wheel strategy including AFMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AFMD
- Rev/Share 0.0545
- Book/Share 1.068
- PB 0.1479
- Debt/Equity 0.7496
- CurrentRatio 1.9306
- ROIC -2.4461
- MktCap 2589318.3006
- FreeCF/Share -4.8098
- PFCF -0.0334
- PE -0.0363
- Debt/Assets 0.3226
- DivYield 0
- ROE -1.9385
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | AFMD | H.C. Wainwright | Buy | Neutral | -- | -- | May 14, 2025 |
| Downgrade | AFMD | Leerink Partners | Outperform | Market Perform | -- | -- | May 13, 2025 |
News
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
Read More
About Affimed N.V. (AFMD)
- IPO Date 2014-09-12
- Website https://www.affimed.com
- Industry Biotechnology
- CEO Dr. Shawn M. Leland Pharm.D., R.Ph.
- Employees 76